Compound Library
Evidence-based research summaries across 9 categories.
Long-acting amylin analogue under investigation in combination with semaglutide (CagriSema). Amylin pathway complements GLP-1 mechanisms for potentially additive weight effects.
Melanocortin receptor agonist studied for sexual function (erectile and arousal pathways), skin pigmentation, and appetite suppression via CNS mechanisms.
Pro-apoptotic peptide that selectively destroys vasculature supplying white adipose tissue. Studied in primate models with dramatic fat reduction results.
Soluble activin receptor type IIB (ActRIIB) fusion protein — potent myostatin pathway inhibitor. Studied for Duchenne muscular dystrophy and muscle wasting. Dramatically increases lean mass in human trials before safety pause.
Endogenous myostatin and activin antagonist. Studied for muscle hypertrophy, fertility, and metabolic effects. Significantly increases lean body mass in animal models. Limited human pharmacokinetic data.
Approved aphthous ulcer treatment (Aphthasol) being repurposed as metabolic compound. Inhibits TBK1 and IKKε kinases, reversing metabolic effects of obesity-induced inflammation. Studied for weight loss, insulin sensitivity, and NASH.
Steroidal SARM with unique dual mechanism: androgen receptor partial agonist AND myostatin inhibitor via follistatin induction. Studied for exceptional anabolic potential with potentially lower androgenic side effects than testosterone. Research compound only.